Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Deflazacort · Emflaza, L-5458

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Ptc Therap

Approved FDA, Feb 2017
PTCT Developer
1 Registered trials

What is Deflazacort?

Deflazacort is a corticosteroid prodrug whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to produce anti-inflammatory and immunosuppressive effects. It is studied in limb-girdle muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Emflaza, L-5458, MDL-458
Drug type
Small molecule
Targets
glucocorticoid receptor (NR3C1)
Mechanism
Agonist of glucocorticoid receptor (NR3C1)
Pathways
anti-inflammatory and immunosuppressive effects
Therapy area
Musculoskeletal
Developer
Ptc Therap (PTCT)
FDA status
Approved as Emflaza (February 9, 2017), NDA208684
UNII
KR5YZ6AE4B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03783923 Phase 3 Limb-Girdle Muscular Dystrophy Terminated PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Limb-Girdle Muscular Dystrophy

Other drugs acting on NR3C1

More from Ptc Therap

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Deflazacort

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.